The effects of intracoronary (IC) thrombolysis therapy in patients with ST-segment elevation myocardial infarction (STEMI) receiving primary percutaneous coronary intervention (PPCI) remain unclear.
Methods:
The meta-analysis was conducted according to the PRISMA statement. All relevant studies were identified by searching the PubMed, EMBASE, Cochrane Library, and Web of Science, with no time or language limitation. The pooled risk ratio (RR) and weighted mean difference (WMD) with a 95% CI were calculated.
Results:
Nine randomized controlled trials involving a total of 1341 patients were included. Compared with the control group, IC thrombolysis in patients with STEMI could reduce the incidence of major adverse cardiac events (MACE; RR 0.632, 95% CI, 0.474-0.843, P = .002) and improve left ventricular ejection fraction (RR 0.343, 95% CI, 0.178-0.509, P < .001) and myocardial microcirculation. However, there was no difference noted in the mortality (RR 0.759, 95% CI, 0.347-1.661, P = .490). The incidence rate of major bleeding and minor bleeding was comparable between the 2 groups.
Conclusions:
Intracoronary thrombolysis was associated with improved MACE and myocardial microcirculation in patients with STEMI having PPCI, though it failed to improve mortality.
IbanezBJamesSAgewallS, et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39: 119–177.
2.
HenriquesJPZijlstraFOttervangerJP, et al.Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002; 23: 1112–1117.
3.
BaineyKRArmstrongPW. Clinical perspectives on reperfusion injury in acute myocardial infarction. AM Heart J. 2014; 167: 637–645.
4.
NiccoliGBurzottaFGaliutoLCreaF. Myocardial no-reflow in humans. J Am Coll Cardiol. 2019;54: 281–292.
5.
BrenerSJCristeaEMehranRDresslerOLanskyAJStoneGW. Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial. Am Heart J. 2011;162: 1044–1051.
6.
ChanWStubDClarkDJ, et al.Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am J Cardiol. 2012;109: 478–485.
7.
KellyRVCrouchEKrumnacherHCohenMGStoufferGA. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv. 2015; 66: 327–332.
8.
KimJSKimJHJangHH, et al.Successful revascularization of coronary artery occluded by massive intracoronary thrombi with alteplase and percutaneous coronary intervention. J Atheroscler Thromb. 2010;17: 768–770.
9.
Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006; 367: 569–578.
10.
EllisSGTenderaMde BelderMA, et al.Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358: 2205–2217.
11.
SezerMOflazHGörenT, et al.Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med. 2007; 356: 1823–1834.
12.
KumarAShariffMDoshiR. Index of microvascular resistance and outcomes following intra-coronary thrombolysis with percutaneous intervention in STEMI: a meta-analysis of randomized control trials. J Thromb Thrombolysis.2020; 49: 487–491.
13.
OremusMWolfsonCPerraultADemersLMomoliFMorideY. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001; 12: 232–236.
14.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269, W64.
15.
CumpstonMLiTPageMJ, et al.Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
16.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088–1101.
17.
PellicciaFGrecoCTanzilliGViceconteNSchiaritiMGaudioC. Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial. J Thromb Thrombolysis. 2020; doi: 10.1007/s11239-020-02157-w.
18.
GibsonCMKumarVGopalakrishnanL, et al.Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). Am J CardioL. 2020;125: 485–490.
19.
WangXLiuHWuH, et al.Safety and efficacy of intracoronary prourokinase administration in patients with high thrombus burden. Coronary Artery Dis. 2020; 31:493–499.
20.
FuYGuXSHaoGZ, et al.Comparison of myocardial microcirculatory perfusion after catheter-administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2019; 93: 839–845.
21.
McCartneyPJEteibaHMaznyczkaAM, et al.Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2019;321: 56–68.
22.
GengWZhangQLiuJ, et al.A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. J Interv Cardiol. 2018;31: 136–143.
23.
ZhaoBLiuLFLiuYQ, et al.Effects of intracoronary low-dose urokinase injection combined with stent implantation in acute STEMI patients on myocardial perfusion and its influence on short-term prognosis. Medical Journal of Chinese People’s liberation Army. 2015;40: 661–665.
24.
SezerMCimenAAslangerE, et al.Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol. 2009; 54: 1065–1071.
25.
PuJDingSGeH, et al.Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017;136: 1462–1473.
26.
PianaRNPaikGYMoscucciM, et al.Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation.1994; 89: 2514–2518.
27.
WhiteCJRameeSRCollinsTJ, et al.Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation. 1996;93: 253–258.
28.
StoneGWMaeharaAWitzenbichlerB, et al.Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307: 1817–1826.
29.
PratiFCapodannoDPawlowskiTR, et al.Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv. 2010; 3: 928–934.
